Alcobra, Ltd.

We are a publicly traded, emerging pharmaceutical company (NASDAQ: ADHD) primarily focused on the development and commercialization of our proprietary drug, METADOXINE EXTENDED RELEASE (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS). MDX is not a stimulant; it works through a different mechanism of action than other ADHD treatments. Alcobra has completed multiple Phase II studies of MDX in adults and adolescents with ADHD and FXS and a Phase III study of MDX in adults with ADHD. The company is currently conducting a second, pivotal Phase III trial of MDX in adult ADHD. Our objective is to develop and commercialize proprietary pharmaceutical products for treatment of central nervous system disorders, and cognitive dysfunctions in particular. We intend to conduct additional clinical trials for our most advanced product (MDX) and, if those trials are successful, seek marketing approval from the U.S. Food and Drug Administration (FDA), and other worldwide regulatory agencies for MDX for the treatment of ADHD in adults and children. We also are advancing clinical studies and commercialization plans for different MDX-based products in additional indications of cognitive dysfunction where there is significant unmet clinical need such as Fragile X Syndrome. OUR VISION: Alcobra, an Israeli corporation, relentlessly pursues creative, unbeaten paths for the identification, development and commercialization of therapeutics for impairing CNS disorders. We are committed to becoming a leading global player in the pharmaceutical industry through disruptive efficiency and innovation.